Evidence map›Paper›PMID 39049057›Full record

ArticleMicrobial cell factories2024

Producing recombinant proteins in Vibrio natriegens.

Matthew Smith, José Sánchez Hernández, Simon Messing, Nitya Ramakrishnan, Brianna Higgins, Jennifer Mehalko, Shelley Perkins, Vanessa E Wall, Carissa Grose, Peter H Frank and 17 more

Abstract read
In one paragraph

Article in Microbial cell factories, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Applied and environmental microbiology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. NMRBiomolecular NMR assignments · 2025
    Article
  9. Article
  10. Detection ofThe Analyst · 2025
    Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Matthew SmithProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
José Sánchez HernándezProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Simon MessingProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Nitya RamakrishnanProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Brianna HigginsProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Jennifer MehalkoProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Shelley PerkinsProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Vanessa E WallProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Carissa GroseProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Peter H FrankProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Julia CreggerProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Phuong Vi LeProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Adam JohnsonProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Mukul SherekarProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Morgan PagonisProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Matt DrewProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Min HongProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Stephanie R T WidmeyerProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
John-Paul DensonProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Kelly SneadProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Ivy PoonProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Timothy WaybrightNCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Allison ChampagneProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Dominic EspositoProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Jane JonesProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
Troy TaylorProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
William GilletteProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA. gillettew@nih.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The diversity of chemical and structural attributes of proteins makes it inherently difficult to produce a wide range of proteins in a single recombinant protein production system. The nature of the target proteins themselves, along with cost, ease of use, and speed, are typically cited as major factors to consider in production. Despite a wide variety of alternative expression systems, most recombinant proteins for research and therapeutics are produced in a limited number of systems: Escherichia coli, yeast, insect cells, and the mammalian cell lines HEK293 and CHO. Recent interest in Vibrio natriegens as a new bacterial recombinant protein expression host is due in part to its short doubling time of ≤ 10 min but also stems from the promise of compatibility with techniques and genetic systems developed for E. coli. We successfully incorporated V. natriegens as an additional bacterial expression system for recombinant protein production and report improvements to published protocols as well as new protocols that expand the versatility of the system. While not all proteins benefit from production in V. natriegens, we successfully produced several proteins that were difficult or impossible to produce in E. coli. We also show that in some cases, the increased yield is due to higher levels of properly folded protein. Additionally, we were able to adapt our enhanced isotope incorporation methods for use with V. natriegens. Taken together, these observations and improvements allowed production of proteins for structural biology, biochemistry, assay development, and structure-based drug design in V. natriegens that were impossible and/or unaffordable to produce in E. coli.

Indexed as

Recombinant ProteinsVibrioEscherichia coliHumansRecombinant Proteinsauto-inductionEscherichia coliisotopic labelingKRAS4bprotein aggregationprotein foldingrecombinant protein expressionsmall GTPaseTEV proteaseVibrio natriegens

Identifiers

PMID39049057
PMCPMC11267860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.